

September 27, 2018

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir,

Sub: Outcome of Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that, *interalia*, the following decisions were taken by Board of Directors of the Company at the meeting held today i.e. September 27, 2018:

1. The Board of Directors have noted and taken on record the resignations tendered by:
 - a) Mr. CT. Renganathan as the Managing Director of the Company effective from closing hours of business on September 30, 2018
 - b) Mr Yugal Sikri as an Independent Director of the Company effective from September 27, 2018
2. Based on the recommendation of the Nomination & Remuneration Committee, the Board of Directors have:
 - a) Appointed Mr Yugal Sikri as an Additional Director and as the Managing Director of the Company with effect from October 1, 2018 for a period of 3 years subject to approval of the Shareholders.
 - b) Approved continuation of Mr. CT. Renganathan as the Whole Time Director of the Company from October 1, 2018 to November 30, 2018 subject to approval of the Shareholders, if any.

Profiles of Mr Yugal Sikri and Mr. CT. Renganathan are enclosed herewith as 'Annexure A' . It may be noted that neither of the two appointees are related to any other Director or Key Managerial Personnel of the Company.


We further wish to inform that in terms of Circular No. NSE/CML/2018/02 dated June 20, 2018 issued by National Stock Exchange of India Limited, and Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 issued by BSE Limited, the two appointees have not been debarred from holding the office of a Director by virtue of any order by SEBI or any other authority.

The meeting commenced at 2.30 p.m. and concluded at 3.30 p.m.

Kindly request you to take the same on record.

Thanking You,

Yours Sincerely
For RPG Life Sciences Limited


Rajesh Shirambekar
Head – Legal & Company Secretary




Encl: Annexure A

Annexure A

1. Appointment of Mr. Yugal Sikri as the Managing Director

Sr	Details of events that need to be provided	Information of such events
1	Reason for change viz. appointment , resignation, removal, death or otherwise	Appointment
2	Date of Appointment/cessation (as applicable) Term of Appointment	October 1, 2018 For a period of 3 years up to September 30, 2021
3	Brief Profile (in case of appointment)	Mr. Sikri is a senior pharma industry professional backed by over 35 years of rich and diverse experience in managing successfully large businesses, building mega-brands and bringing in business turnarounds. He holds Masters in Pharmacy from IIT, BHU, Master in Marketing Management from Jamnalal Bajaj Institute of Management studies and Certificates in Management from Thunderbird and Harvard Business Schools. Mr. Sikri is currently Chairman, Pharmaceutical Management at NMIMS School of Business Management, where he is credited with transforming its pharmaceutical management program, forging a strong academia-industry partnership and launching thought leadership initiatives. He has been serving on the Board of RPG Life Sciences for past 2 years as an Independent Director. He was invited to be a mentor at Atal Incubation Center, a Government of India-NMIMS initiative, encouraging entrepreneurship amongst young start-ups. His work experiences come from senior leadership assignments at GlaxoSmithKline, Warner Lambert/Pfizer, Novartis, Ranbaxy and RPG Life Sciences that includes Region Head of India, Srilanka and Nepal and Global Head of Marketing (Commercial functions) at Ranbaxy. Recipient of a number of awards, both global and country level, he has been invited as Chairman/Keynote speaker at a number of reputed management institutes and industry platforms such as CPHI, CII, IPC, OPPI, IDMA, National CIO and Bio Pharma Conferences and Jury for Industry Awards. He has been the member of the Steering Committee of prestigious McKinsey's India 2020 publication and speaker at McKinsey CEO forum. He has also been the Vice-Chair of OPPI Marketing Committee and contributed to designing Industry's Code of Marketing Practices, Marketing Excellence Awards and Sales Force Excellence initiatives.
4	Disclosure of relationship between Directors (in case of appointment of a Director)	Mr. Yugal Sikri is not related to any Director of the Company



2. Appointment of Mr. CT. Renganathan as a Whole Time Director

Sr	Details of events that need to be provided	Information of such events
1	Reason for change viz. appointment , resignation, removal, death or otherwise	Appointment
2	Date of Appointment/cessation (as applicable) Term of Appointment	October 1, 2018 For a period of 2 months up to November 30, 2018
3	Brief Profile (in case of appointment)	<p>Mr. CT. Renganathan has been working with the Company as Managing Director for more than 3 years and in the Pharmaceutical Industry for the last three decades in different capacities of Sales, Marketing & General Management, both in India as well as International Markets such as Malaysia, Singapore & Brunei. He has worked with organisations like GSK India, Boston Scientific, Eli Lilly, etc.</p> <p>Mr. Renganathan was honoured with various prestigious awards by the organisations he worked. Some of the major awards he won were "Best Unit Manager", "Oncology Best Launch", "President's Award for Stiefel Integration and Performance", "Votrient Launch" etc.</p> <p>Mr.Renganathan is also a fellow member of the Institute of Directors.</p>
4	Disclosure of relationship between Directors (in case of appointment of a Director)	Mr. CT. Renganathan is not related to any Director of the Company

